Victory Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.83M | Sell |
103,161
-32,881
| -24% | -$1.92M | ﹤0.01% | 1266 |
|
|
2025
Q4 | $8.08M | Sell |
136,042
-90,387
| -40% | -$4.92M | ﹤0.01% | 1120 |
|
|
2025
Q3 | $12.3M | Buy |
226,429
+125,717
| +125% | +$7.19M | 0.01% | 1035 |
|
|
2025
Q2 | $5.54M | Buy |
100,712
+30,478
| +43% | +$1.79M | ﹤0.01% | 1282 |
|
|
2025
Q1 | $4.96M | Sell |
70,234
-207,505
| -75% | -$14M | 0.01% | 1282 |
|
|
2024
Q4 | $18.3M | Buy |
277,739
+176,514
| +174% | +$11.8M | 0.02% | 879 |
|
|
2024
Q3 | $7.12M | Buy |
101,225
+25
| +0% | +$2.09K | 0.01% | 1197 |
|
|
2024
Q2 | $8.33M | Buy |
101,200
+13,234
| +15% | +$1.1M | 0.01% | 1128 |
|
|
2024
Q1 | $7.68M | Sell |
87,966
-11,608
| -12% | -$1.04M | 0.01% | 1135 |
|
|
2023
Q4 | $9.6M | Sell |
99,574
-20,646
| -17% | -$1.83M | 0.01% | 1071 |
|
|
2023
Q3 | $10.6M | Buy |
120,220
+8,645
| +8% | +$769K | 0.01% | 987 |
|
|
2023
Q2 | $9.67M | Sell |
111,575
-41,321
| -27% | -$3.89M | 0.01% | 1054 |
|
|
2023
Q1 | $14.9M | Buy |
152,896
+22,796
| +18% | +$2.36M | 0.02% | 889 |
|
|
2022
Q4 | $13.5M | Sell |
130,100
-605,370
| -82% | -$56.8M | 0.02% | 924 |
|
|
2022
Q3 | $62.3M | Buy |
735,470
+23,652
| +3% | +$2.11M | 0.07% | 375 |
|
|
2022
Q2 | $59M | Sell |
711,818
-1,498
| -0.2% | -$119K | 0.07% | 410 |
|
|
2022
Q1 | $58M | Sell |
713,316
-23,155
| -3% | -$1.94M | 0.06% | 460 |
|
|
2021
Q4 | $65.1M | Buy |
736,471
+83
| +0% | +$6.85K | 0.06% | 456 |
|
|
2021
Q3 | $56.9M | Buy |
736,388
+19,903
| +3% | +$1.57M | 0.06% | 499 |
|
|
2021
Q2 | $59.8M | Sell |
716,485
-1,097
| -0.2% | -$87K | 0.06% | 481 |
|
|
2021
Q1 | $54.2M | Sell |
717,582
-27,874
| -4% | -$2.28M | 0.06% | 515 |
|
|
2020
Q4 | $65.4M | Sell |
745,456
-24,817
| -3% | -$1.97M | 0.07% | 418 |
|
|
2020
Q3 | $58.6M | Buy |
770,273
+22,534
| +3% | +$2.28M | 0.08% | 404 |
|
|
2020
Q2 | $92.2M | Buy |
747,739
+501,073
| +203% | +$49.8M | 0.12% | 219 |
|
|
2020
Q1 | $20.8M | Buy |
246,666
+126,529
| +105% | +$10.9M | 0.02% | 872 |
|
|
2019
Q4 | $10.2M | Buy |
120,137
+3,763
| +3% | +$284K | 0.01% | 1007 |
|
|
2019
Q3 | $7.84M | Sell |
116,374
-75,316
| -39% | -$5.8M | 0.01% | 1048 |
|
|
2019
Q2 | $16.4M | Sell |
191,690
-192,105
| -50% | -$16.4M | 0.03% | 668 |
|
|
2019
Q1 | $34.1M | Sell |
383,795
-152,785
| -28% | -$14.2M | 0.08% | 405 |
|
|
2018
Q4 | $45.7M | Sell |
536,580
-50,158
| -9% | -$4.77M | 0.11% | 268 |
|
|
2018
Q3 | $56.9M | Sell |
586,738
-98,197
| -14% | -$9.8M | 0.12% | 272 |
|
|
2018
Q2 | $64.5M | Sell |
684,935
-67,070
| -9% | -$5.87M | 0.14% | 211 |
|
|
2018
Q1 | $61M | Sell |
752,005
-35,450
| -5% | -$3.04M | 0.13% | 228 |
|
|
2017
Q4 | $70.2M | Sell |
787,455
-67,592
| -8% | -$5.88M | 0.15% | 196 |
|
|
2017
Q3 | $79.6M | Sell |
855,047
-1,868
| -0.2% | -$165K | 0.18% | 159 |
|
|
2017
Q2 | $77.8M | Sell |
856,915
-68,375
| -7% | -$6.22M | 0.18% | 157 |
|
|
2017
Q1 | $81.2M | Sell |
925,290
-498,735
| -35% | -$44.4M | 0.19% | 155 |
|
|
2016
Q4 | $118M | Buy |
1,424,025
+155,959
| +12% | +$13.4M | 0.3% | 73 |
|
|
2016
Q3 | $117M | Buy |
1,268,066
+83,272
| +7% | +$7.84M | 0.33% | 49 |
|
|
2016
Q2 | $92.2M | Sell |
1,184,794
-155,272
| -12% | -$13.2M | 0.37% | 51 |
|
|
2016
Q1 | $111M | Buy |
1,340,066
+3,381
| +0.3% | +$275K | 0.46% | 31 |
|
|
2015
Q4 | $140M | Buy |
1,336,685
+6,782
| +0.5% | +$708K | 0.58% | 12 |
|
|
2015
Q3 | $140M | Sell |
1,329,903
-17,246
| -1% | -$2.3M | 0.58% | 17 |
|
|
2015
Q2 | $184M | Sell |
1,347,149
-42,131
| -3% | -$5.22M | 0.68% | 11 |
|
|
2015
Q1 | $173M | Sell |
1,389,280
-48,022
| -3% | -$5.09M | 0.62% | 11 |
|
|
2014
Q4 | $130M | Buy |
+1,437,302
| New | +$120M | 0.48% | 36 |
|
Other funds holding BMRN
VCM
VPM
Victory Capital Management's BMRN Position: Q1 2026 in Review
Victory Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 24% in Q1 2026, selling an estimated $1.92M and leaving 103,161 shares worth $5.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.
Victory Capital Management first reported a position in BMRN in Q4 2014 and has held it in 46 quarters since. The position peaked at $184M in Q2 2015. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Victory Capital Management held 103,161 shares of BioMarin Pharmaceuticals worth $5.83M as of Q1 2026.
- Victory Capital Management sold 32,881 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.92M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1266 holding.
- Victory Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- Victory Capital Management's BioMarin Pharmaceuticals position peaked at $184M in Q2 2015.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.